BioCryst Pharmaceuticals BCRX Lease Payments
Lease Payments at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeasePayments.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's lease payments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's lease payments?
- BioCryst Pharmaceuticals (BCRX) reported lease payments of $405K in Q1 2026.
- How has BioCryst Pharmaceuticals's lease payments changed year-over-year?
- BioCryst Pharmaceuticals's lease payments increased by 5.2% year-over-year, from $385K to $405K.
- What is the long-term trend for BioCryst Pharmaceuticals's lease payments?
- Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's lease payments has grown at a -0.5% compound annual growth rate (CAGR), from $1.49M to $1.47M.
- What does lease payments mean?
- This metric tracks the total cash outflows required to satisfy operating lease obligations for facilities, equipment, or other assets. Unlike finance leases, these are generally treated as operating expenses. It is a key component of the company's recurring cash burn and fixed operational overhead.